The CETLAM group performed NPM1 qPCR-MRD monitoring on 110 patients with ELN favorable NPM1mut AML in first remission (CR1) after standard chemotherapy, of which 33 patients experienced molecular failure, defined as failure to achieve NPM1-MRD ≤ 0.05% after consolidation therapy (n = 11) or MRD relapse (n = 22). The gene discussed is NPM1; the disease is acute myeloid leukemia.